Drug intelligence / Profile preview

cisplatin + hydrazine sulfate + vinblastine

Development stage: Unknown
Lead developer: Michigan State University
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

A chemotherapy regimen combining cisplatin, hydrazine sulfate, and vinblastine. This combination was primarily studied for the treatment of non-small-cell lung cancer (NSCLC). Cisplatin is a platinum-based chemotherapy agent that interferes with DNA replication. Hydrazine sulfate was investigated as both an anticancer agent and for preventing cachexia (weight loss) in cancer patients. Vinblastine is a vinca alkaloid that prevents microtubule formation, interfering with cell division.

Targets

TUBB (Tubulin (alpha and beta subunits))DNA

Beyond the preview

Go deeper on cisplatin + hydrazine sulfate + vinblastine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cisplatin + hydrazine sulfate + vinblastine.

Explore the full profile